← Leaderboards
Mark Sebastian Sulkowski
Indiana University Indianapolis
$12,713,668
Attributed
$17,943,355
Total exposure
14
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$17,943,355 · 14
By mechanism
R01$15,846,852 · 2
K24$1,203,370 · 1
M01$881,133 · 10
R13$12,000 · 1
Top collaborators
- Naga P. Chalasani5 shared
- Rohit Loomba5 shared
- Raymond F. Schinazi1 shared
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Chunyan He$1,618,762
- Sharon Janell Miller$136,817
- Kaice Lafavers$915,687
- Steven J. Higbee$79,183
- Linda Ann Headrick$587,500
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchPersonsLiver DiseasesLiverHepatitis CHepatitis C VirusVirus DiseasesCessation Of LifePrevalenceProgramsHiv InfectionsInnovationIncentivesCohortBaseUnited StatesInfectionPharmaceutical PreparationsCaringFundingInjecting Drug UserEffectivenessEligibility DeterminationSafety
Grant awards (44)
Ancillary Studies of NAFLD and NASH in HIV infected Adults$1,464,756
R01 · FY2024 · DK
Ancillary Studies of NAFLD and NASH in HIV infected Adults$1,542,615
R01 · FY2023 · DK
Ancillary Studies of NAFLD and NASH in HIV infected Adults$1,558,981
R01 · FY2022 · DK
Midcareer Investigator Award in Patient-Oriented Research (Parent K24)$122,036
K24 · FY2022 · DA · contact PI
HEP DART 2021: FRONTIERS IN DRUG DEVELOPMENT FOR HEPATOLOGY$12,000
R13 · FY2022 · AI
Ancillary Studies of NAFLD and NASH in HIV infected Adults$1,566,039
R01 · FY2021 · DK
Midcareer Investigator Award in Patient-Oriented Research (Parent K24)$122,036
K24 · FY2021 · DA · contact PI
Ancillary Studies of NAFLD and NASH in HIV infected Adults$1,703,139
R01 · FY2020 · DK
Midcareer Investigator Award in Patient-Oriented Research (Parent K24)$122,036
K24 · FY2020 · DA · contact PI
Midcareer Investigator Award in Patient-Oriented Research (Parent K24)$122,036
K24 · FY2019 · DA · contact PI
HCV Disease Management in HIV-HCV Coinfected IDUs$706,389
R01 · FY2018 · DA · contact PI
Midcareer Investigator Award in Patient-Oriented Research (Parent K24)$122,036
K24 · FY2018 · DA · contact PI
HCV Disease Management in HIV-HCV Coinfected IDUs$706,777
R01 · FY2017 · DA · contact PI
HCV Disease Management in HIV-HCV Coinfected IDUs$700,614
R01 · FY2016 · DA · contact PI
Patient Oriented Research in Hepatitis C-infected Injection Drug Users$118,638
K24 · FY2016 · DA · contact PI
HCV Disease Management in HIV-HCV Coinfected IDUs$697,750
R01 · FY2015 · DA · contact PI
Patient Oriented Research in Hepatitis C-infected Injection Drug Users$118,638
K24 · FY2015 · DA · contact PI
HCV Disease Management in HIV-HCV Coinfected IDUs$716,284
R01 · FY2014 · DA · contact PI
Patient Oriented Research in Hepatitis C-infected Injection Drug Users$118,638
K24 · FY2014 · DA · contact PI
Patient Oriented Research in Hepatitis C-infected Injection Drug Users$118,638
K24 · FY2013 · DA · contact PI
HCV Disease Management in HIV- HCV Coinfected IDUs$408,118
R01 · FY2012 · DA · contact PI
Patient Oriented Research in Hepatitis C-infected Injection Drug Users$118,638
K24 · FY2012 · DA · contact PI
HCV Disease Management in HIV- HCV Coinfected IDUs$417,799
R01 · FY2011 · DA · contact PI
HCV Disease Management in HIV- HCV Coinfected IDUs$426,264
R01 · FY2010 · DA · contact PI
HCV Disease Management in HIV- HCV Coinfected IDUs$419,807
R01 · FY2009 · DA · contact PI
HCV Disease Management in HIV- HCV Coinfected IDUs$402,468
R01 · FY2008 · DA · contact PI
Management/Hepatitis C/HIV-infected and Uninfected IDU's$437,887
R01 · FY2007 · DA · contact PI
MANAGEMENT OF HEPATITIS C IN HIV-INFECTED & UNINFECTED IDUS$152,923
M01 · FY2007 · RR · contact PI
ACTG 5178$83,524
M01 · FY2007 · RR · contact PI
Management/Hepatitis C/HIV-infected and Uninfected IDU's$407,906
R01 · FY2006 · DA · contact PI
MANAGEMENT OF HEPATITIS C IN HIV-INFECTED AND UNINFECTED IDUS$265,768
M01 · FY2006 · RR · contact PI
ACTG 5178$105,464
M01 · FY2006 · RR · contact PI
HEPATIC STEATOSIS AND MEASURES OF METABOLIC AND MORPHOLOGIC STATUS IN HIV/HCV$1,055
M01 · FY2006 · RR · contact PI
Management/Hepatitis C/HIV-infected and Uninfected IDU's$483,899
R01 · FY2005 · DA
MANAGEMENT OF HEPATITIS C IN HIV-INFECTED AND UNINFECTED IDUS$218,871
M01 · FY2005 · RR
ACTG 5178$33,618
M01 · FY2005 · RR
ACTG A5127$4,292
M01 · FY2005 · RR
Management/Hepatitis C/HIV-infected and Uninfected IDU's$564,980
R01 · FY2004 · DA
ACTG A5088$9,042
M01 · FY2004 · RR
ACTG A5127$6,576
M01 · FY2004 · RR
Management/Hepatitis C/HIV-infected and Uninfected IDU's$514,380
R01 · FY2003 · DA
PEG INTERFERON A2A AND RIBAVIRIN IN CHRONIC HEPATITIS C$0
M01 · FY2002 · RR
PEG INTERFERON A2A AND RIBAVIRIN IN CHRONIC HEPATITIS C$0
M01 · FY2001 · RR
PEG INTERFERON A2A AND RIBAVIRIN IN CHRONIC HEPATITIS C$0
M01 · FY2000 · RR